Lamivudine as initial treatment for chronic hepatitis B in the United States

New England Journal of Medicine

Volumn 341, Issue 17, 1999, Pages 1256-1263

  Dienstag, Jules L ^d   Schiff, Eugene R ^e   Wright, Teresa L ^e   Perrillo, Robert P ^a   Hann, Hie Won L ^b   Goodman, Zachary ^e   Crowther, Lynn ^c   Condreay, Lynn D ^c   Woessner, Mary ^c   Rubin, Marc ^c   Brown, Nathaniel A ^c  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c GLAXOSMITHKLINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; PLACEBO;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEROCONVERSION; SLEEP DISORDER; UNITED STATES;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; UNITED STATES;

EID: 0033592764     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199910213411702     Document Type: Article

References (35)

1. Dienstag JL, Isselbacher KJ. Acute viral hepatitis. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., eds. Harrison's principles of internal medicine. 14th ed. Vol. 2. New York: McGraw-Hill, 1998:1677-92.
2. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa 2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
3. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.
4. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-23.
5. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88:8495-9.
6. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
7. Honkoop P, de Man RA, Niesters HGM, et al. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudinc therapy. J Viral Hepat 1998;5:307-12.
8. Tyrrell DLJ, Mitchell MC, De Man RA, et al. Phase II trial of lamivudine for chronic hepatitis B. Hepatology 1993;18:112A. abstract.
9. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258-63.
10. Lai C-L, Chien R-N, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
11. Seeff LB, Koff RS. Evolving concepts of the clinical and serologic consequences of hepatitis B virus infection. Semin Liver Dis 1986;6:11-22.
12. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991;11:84-92.
13. Beasley RP, Hwang L-Y. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983;147:185-90.
14. Seeff LB, Bcebe GW, Hoofhagk JH, et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987;316:965-70.
15. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987; 92:1844-50.
16. Perrillo RP. Factors influencing response to interferon in chronic hepatitis B: implications for Asian and western populations. Hepatology 1990; 12:1433-5.
17. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
18. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995;15:70-81.
19. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997;26:Suppl 1:83S-88S.
20. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
21. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-3.
22. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-7.
23. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatiris-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-2.
24. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudinc. Hepatology 1998;27:1670-7.
25. Peace KE, ed. Biopharmaceutical statistics for drug development. New York: Marcel Dekker, 1988.
26. Schiff E, Cianciara J, Kowdley K, et al. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials. Hepatology 1998;Suppl:28:163A. abstract.
27. Honkoop P, de Man RA, Heitjink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet 1995;346:1156-7.
28. Heathcote J, Schalm SW, Cianciara J, et al. Lamivudine and Intron A combination treatment in patients with chronic hepatitis B infection. J Hepatol 1998;28:Suppl 1:43. abstract.
29. Schiff E, Karayalcin S, Grimm I, et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 1998;Suppl:28: 388A. abstract.
30. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
31. Lau DT-Y, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-7.
32. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-34.
33. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-6.
34. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628-33.
35. Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B. Hepatology 1996;Suppl:24:188A. abstract.